

Press Release

BzRzAzlZn Biotechnology Research And Information Network AG and Genencor collaborate to develop new enzyme product platform

ZWINGENBERG, GERMANY, -- September, 2004 -- BRAIN Biotechnology AG today announces an R&D agreement with Genencor International. BRAIN will use its extensive metagenome® and microbial resources to supplement new protein backbones towards the development of an enzyme platform. The research will be coordinated by Genencor's European research facility in Leiden, The Netherlands.

BRAIN will use their LIL® and ABEL® metagenomic libraries and certain microbial isolates for screening and deliver characterized developmental enzyme candidates and corresponding genes to Genencor. The libraries are constructed with proprietary technologies at BRAIN and contain several thousand complete genomes of previously uncultivated microbial organisms. BRAIN's metagenome technologies enable rapid and thorough genetic exploitation of the resources not previously accessible. Genencor will evaluate the candidates and combine their knowledge base with internal capabilities to develop potential enzyme products.

"BRAIN's resources and technologies are an ideal extension of our internal natural isolate and genomic screening capabilities," said Dr. Wolfgang Aehle, Genencor senior scientist.

"We are proud to announce a partnership with the world's 20th largest Biotech-Company by revenues", says Dr. Holger Zinke, Chairman of the Board of Directors at BRAIN. "As a privately financed research and technology company we are well positioned in the emerging field of White Biotechnology. We are happy to start a collaboration with a global leader in enzyme technology and together create product value". "Our metagenome

contact:

BzRzAzlZn
Biotechnology Research
And Information Network AG
Dr. Jürgen Eck
Darmstädter Str. 34
64673 Zwingenberg

ph.: +49-(0)6251-9331-0
fax: +49-(0)6251-9331-11
e-mail: je@brain-biotech.de
www.brain-biotech.de

Genencor International B.V.
Dr. Wolfgang Aehle
P.O. Box 218
2300 AE Leiden
The Netherlands

ph.: +31-(0)71-5686-116
fax: +31-(0)71-5686-130
e-Mail: waehle@genencor.com
www.genencor.com

resources are also key to novel proprietary backbones for novel products. Our efforts and investments in building up our resource-portfolio increasingly pay off.” added Dr. Jürgen Eck, CSO at BRAIN.

The agreement is an outstanding example of doing business in the emerging field of White Biotechnology in Europe. White Biotechnology, a term promoted by EuropaBio for industrial Biotechnology is a well - established, internationally competitive third column of Biotechnology in Europe.

About Brain


BRAIN Biotechnology Research and Information Network AG (www.brain-biotech.de) is an innovative company focusing on the discovery and development of novel enzymes and bioactives. Its novel EvoSolution® technology platform combines the untapped biodiversity of microorganisms and plants with modern methods of molecular biology. The company located in Zwingenberg within the research and industrial region Rhine-Main-Neckar has at its disposal a comprehensive BioArchive with over 100 million genes of unique and non-cultivable microorganisms. Based on these resources BRAIN identifies novel technical enzymes for biotechnological production and synthesis processes (biotransformation) in the chemical and life science industries as well as new bioactive substances and lead candidates for the pharmaceutical and cosmetics market, and develops the basis for their large-scale industrial production. The company, which was founded in Darmstadt in 1993, currently employs a staff of 40.

About Genencor

Genencor is a diversified biotechnology company that develops and delivers innovative products and services into the healthcare, agri-processing, industrial and consumer markets. Using an integrated set of technology platforms, Genencor's products deliver innovative and sustainable solutions to improve the quality of life. Genencor traces its history to 1982 and has grown to become a leading biotechnology company, with over \$380 million in year 2003 annual revenues. Genencor has principal offices in Palo Alto, California; Rochester, New York; and Leiden, the Netherlands.

Pictures and text

Text and picture are available under www.brain-biotech.de ("News").



Novel enzymes and comprehensive enzyme libraries from non-cultivated microorganisms are identified by BRAIN.

© BRAIN AG, Zwingenberg - reprint permitted with
byline